Baidu
map

2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理

2018-08-02 澳大利亚国家心脏基金会 Med J Aust. 2018 Aug 2.

2018年,澳大利亚国家心脏基金会(NHFA)联合澳大利亚和新西兰心脏学会(CSANZ)共同发布了心房颤动的诊断和管理指南。指南提供了关于房颤患者的标准化评估和管理建议,涉及房颤的筛查,预防,诊断检查,急慢性房颤的管理包括抗心律失常治疗以及消融治疗,卒中预防,抗凝治疗以及多学科管理等。

中文标题:

2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理

英文标题:

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.

发布日期:

2018-08-02

简要介绍:

2018年,澳大利亚国家心脏基金会(NHFA)联合澳大利亚和新西兰心脏学会(CSANZ)共同发布了心房颤动的诊断和管理指南。指南提供了关于房颤患者的标准化评估和管理建议,涉及房颤的筛查,预防,诊断检查,急慢性房颤的管理包括抗心律失常治疗以及消融治疗,卒中预防,抗凝治疗以及多学科管理等。 

拓展指南:房颤相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理)] GetToolGuiderByIdResponse(projectId=1, id=98f841c00162a09b, title=2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理, enTitle=National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018., guiderFrom=Med J Aust. 2018 Aug 2., authorId=null, author=, summary=2018年,澳大利亚国家心脏基金会(NHFA)联合澳大利亚和新西兰心脏学会(CSANZ)共同发布了心房颤动的诊断和管理指南。指南提供了关于房颤患者的标准化评估和管理建议,涉及房颤的筛查,预防,诊断检查,急慢性房颤的管理包括抗心律失常治疗以及消融治疗,卒中预防,抗凝治疗以及多学科管理等。 , cover=, journalId=null, articlesId=null, associationId=412, associationName=澳大利亚国家心脏基金会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Aug 02 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年,澳大利亚国家心脏基金会(NHFA)联合澳大利亚和新西兰心脏学会(CSANZ)共同发布了心房颤动的诊断和管理指南。指南提供了关于房颤患者的标准化评估和管理建议,涉及房颤的筛查,预防,诊断检查,急慢性房颤的管理包括抗心律失常治疗以及消融治疗,卒中预防,抗凝治疗以及多学科管理等。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>房颤</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=c35121c00162226a" title="2018 欧洲联合共识声明:房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理" target=_blank>2018 欧洲联合共识声明:房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=445b61c0015e2325" title="2018 EHRA实践指导:房颤患者应用非维生素K拮抗剂口服抗凝药" target=_blank>2018 EHRA实践指导:房颤患者应用非维生素K拮抗剂口服抗凝药</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=239281c00151e6c5" title="2017 EHRA/ESC共识文件:心脏瓣膜病相关性房颤的抗栓治疗" target=_blank>2017 EHRA/ESC共识文件:心脏瓣膜病相关性房颤的抗栓治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=04ad11c00151229a" title="2017 EHRA共识文件:心房颤动的筛查" target=_blank>2017 EHRA共识文件:心房颤动的筛查</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f42101c001a48930" title="2016 SBC指南:心房颤动(执行纲要)" target=_blank>2016 SBC指南:心房颤动(执行纲要)</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E6%88%BF%E9%A2%A4" target=_blank>有关房颤更多指南</a></ul>, tagList=[TagDto(tagId=367, tagName=心房颤动)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9764, appHits=858, showAppHits=0, pcHits=5699, showPcHits=4130, likes=157, shares=19, comments=3, approvalStatus=1, publishedTime=Mon Aug 06 21:01:21 CST 2018, publishedTimeString=2018-08-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 06 21:01:21 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 12:06:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理)])
2018 NHFA/CSANZ临床指南:心房颤动的诊断和管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=925693, encodeId=16b592569373, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:50:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925686, encodeId=263992568633, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:14 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336906, encodeId=4fc633690631, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Aug 06 23:02:00 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2021-02-20 1257d324m68暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=925693, encodeId=16b592569373, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:50:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925686, encodeId=263992568633, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:14 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336906, encodeId=4fc633690631, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Aug 06 23:02:00 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2021-02-20 1257d324m68暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=925693, encodeId=16b592569373, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:50:52 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925686, encodeId=263992568633, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa782569271, createdName=1257d324m68暂无昵称, createdTime=Sat Feb 20 07:49:14 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336906, encodeId=4fc633690631, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Aug 06 23:02:00 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2018-08-06 医者仁心5538

    学习了

    0

Baidu
map
Baidu
map
Baidu
map